In this part of the podcast, David Li, CEO and co-founder of Meliora Therapeutics, reflects on his experience helping build Everest Detection around the challenge of finding lung cancer earlier. He discusses the potential of a noninvasive, blood-based test, why lung cancer can be difficult to detect in blood, and how access to early-stage clinical samples helped the team investigate the problem.
Podden och tillhörande omslagsbild på den här sidan tillhör
Excedr. Innehållet i podden är skapat av Excedr och inte av,
eller tillsammans med, Poddtoppen.
